Document is current
Any future updates will be listed below
-
Authors
Slade, Michael https://orcid.org/0000-0001-8092-6644
Martin, Thomas G.
Nathwani, Nitya
Fiala, Mark A. https://orcid.org/0000-0002-0208-5023
Rettig, Michael P.
Gao, Feng
Deol, Abhinav
Buadi, Francis K. https://orcid.org/0000-0003-3214-0203
Kaufman, Jonathan L. https://orcid.org/0000-0002-5687-6429
Hofmeister, Craig C. https://orcid.org/0000-0003-4816-1607
Gregory, Tara K.
Berdeja, Jesus https://orcid.org/0000-0003-4362-0376
Chari, Ajai
Rosko, Ashley
Vij, Ravi
-
Funding
Funding for this research was provided by:
Takeda, The Binding Site and Adapative Biotechnology provided material support for the research described in this manuscript.
- License Information
-
More Information
Article History
Received: 17 June 2022
Revised: 18 August 2022
Accepted: 23 August 2022
First Online: 16 September 2022
Competing interests
: MS receives research funding from SecuraBio. RV receives grant support from Takeda, BMS, and Sanofi, serves on the advisory boards of Takeda, BMS, Sanofi, Legend, Biegene, Oncopeptides. Adaptive, GSK, and Pfizer and serves as a consultant for Harpoon. CCH receives research funds as principal investigator from BMS/Celgene, Nektar, Oncolytic therapeutics and Sanofi, serves on the advisory boards of Janssen, BMS, GlaxoSmithKline, Oncopeptides, Sanofi and BlueBirdBio and receives patent funds from Recursion pharmaceuticals. JB reports institutional research support from Abbvie, Acetylon, Amgen, Bluebird bio, BMS, Celgene, Celularity, CRISPR Therapeutics, EMD Sorono, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Lilly, Novartis, Poseida, Sanofi, Takeda, and Teva and receive consultancy payments from Bluebird bio, BMS, Celgene, CRISPR Therapeutics, Janssen, Kite Pharma, Legend Biotech, SecuraBio, and Takeda. MAF, FG, FKB, TKG, AR, NN, TGM, AD, JLK, AC and MPR declare no relevant conflicts of interest.
